A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/7088 (2006.01) A61K 48/00 (2006.01) A61P 29/00 (2006.01) A61P 37/08 (2006.01) C07K 16/40 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2340936
A pharmaceutical composition for the treatment or prophylaxis of disorders is described in which the overproduction of sCD23 is implicated. This composition comprises an inhibitor for the formation of human soluble CD23 which inhibitor decreases or blocks selectively the activity of the metallo- protease ADAM9 which otherwise mediates the shedding of sCD23 in human B-cell lines. Also described is a pharmaceutical composition wherein the inhibitor for the formation of human soluble CD23 is a monoclonal or polyclonal antibody directed against the metalloprotease ADAM9 or wherein the inhibitor is an antisense oligonucleotide which is specific for c-myc. Such a pharmaceutical composition may be used in a method for selectively inhibiting the formation of ADAM9 as well as the formation of sCD23. It is a suitable medicament against inflammatory disorders, autoimmune diseases and allergy.
Fetherstonhaugh & Co.
Frey Jurgen
Xerion Pharmaceuticals Ag
LandOfFree
Inhibitors for the formation of soluble human cd23 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors for the formation of soluble human cd23, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors for the formation of soluble human cd23 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1701565